Skip to main content

Research projects developing a new drug for breast cancer and materials with novel properties win the BIST Ignite Awards

17 Jan 23

Images

Participants

Contact

Image
Press and Communications Officer
Tel.+34 93 40 37255
  • The fifth edition of the awards funds the EXPLODE-TNBC project, led by researchers at CRG and IRB Barcelona, and the Terafox project, led by researchers at ICFO and ICN2
  • Since 2016, the BIST Ignite Programme fosters disruptive multidisciplinary research projects among the BIST community

The research projects EXPLODE-TNBC, led by Dr. Antoni Riera (IRB Barcelona) and Dr. Sara Sdelci (CRG), and TeraFox, led by Dr. Ekaterina Khestanova (ICFO) and Dr. David Pesquera (ICN2), have won the 2022 BIST Ignite Awards. These awards recognise the two most promising projects among the five selected in the “seed phase” of the fifth edition of the BIST Ignite Programme, an initiative by the Barcelona Institute of Science and Technology (BIST) to promote multidisciplinary ground-breaking research through collaboration among groups from the seven research centres of the BIST community. Since its launch in 2016, the BIST Ignite Programme has invested more than one million euros in cutting-edge research projects.

The two winning projects will receive 50,000 euros each to begin a second research phase, which will further advance their results. The first results of these projects will be presented in the 2023 BIST Conference, in November. 

EXPLODE-TNBC: Seeking a targeted therapy for triple-negative breast cancer

This project is made possible through the collaboration of researchers with different expertise  -Dr. Sdelci and Dr. Riera- and a common goal: to improve the outcome of triple-negative breast cancer (TNBC) treatments. TNBCs, which represent 15% of all breast cancers, are currently treated with chemotherapeutic regimens, which unfortunately have very poor results.

Previous results from the Sdelci Lab had shown that the enzyme IMPDH2 is enriched in the cell nucleus of TNBC cells. The cytoplasmic function of IMPDH2 is well studied and it is required for normal cell homeostasis. Therefore, inhibiting the enzyme would have toxic effects. Dr. Sara Sdelci, leader of the Cancer Epigenetics and Metabolism group at the Centre for Genomic Regulation (CRG), thought that degrading the IMPDH2 enzyme located only in the cell nucleus could be a good approach to treat this type of cancer. To do so, she teamed with Dr. Antoni Riera, head of the Research Unit on Asymmetric Synthesis at the Institute for Research in Biomedicine (IRB Barcelona), who is an expert in the synthesis of biologically active compounds, including PROTACs. These compounds are bifunctional molecules that can induce the degradation of a targeted protein using the cellular natural mechanisms. In the first phase of the project, Riera’s research group synthetized several bifunctional molecules that were test at Sdelci’s laboratory. Although the expected IMPDH2 degradation did not occur with the tested PROTACs, Sdelci’s research group advanced on understanding the biology behind the unexpected nuclear accumulation of this enzyme in TNBC, discovering its implication in protecting cancer cells from death.

Now, thanks to the BIST Ignite Award, the multidisciplinary team will continue working in the development of the presumed therapeutic molecules and test them in combination with DNA damage agents in patient-derived tumoroids. “We are very determined in identifying IMPDH2 nuclear PROTACs molecules that we propose for the treatment of TNBC”, explains Dr. Riera. “We expect that these compounds will give fewer adverse effects than commercially available IMPDH2 inhibitors, and should be more effective in the repression of TNBC growth because they specifically target the nuclear action of the enzyme”, adds Dr. Sdelci.

TeraFox: Modulating properties of matter with light

The TeraFox project brings together two research groups with complementary material science and photonics backgrounds. Led by the postdoctoral researchers at ICFO, Dr. Ekaterina Khestanova, and at Catalan Institute of Nanoscience and Nanotechnology (ICN2), Dr. David Pesquera, the project seeks to develop a more efficient method to control the functional properties of Transition Metal Oxides (TMOs). These materials are of great interest in research and industry due to the stunning variety of their electronic and magnetic properties.

Traditionally, attempts to manipulate TMOs properties have been carried out by altering the chemical composition or acting on the structure of the compound. Researchers at ICN2 and ICFO teamed up to try a different approach: to use light.

In the first phase of the BIST Ignite project researchers targeted the atomic vibrations  –phonons, which in TMOs govern many of the materials interesting properties and are known to be susceptible to Terahertz (THz) light-electromagnetic radiation that lies between the microwave and far infrared. By neighbouring thin films of the selected TMO materials with THz high-refraction-index medium (which works to concentrate the THz field), the researchers found indications of modified atomic vibrations and enhanced responses to electrical fields in these TMO compounds. These preliminary results look promising and thanks to the BIST Ignite Award, will be explored further.

“We have initiated an original and exciting research direction which hopefully will be fruitful and impactful for the scientific community”, explains Dr. Khestanova. “The possibility of engineering properties of TMO’s with photonic cavities will open up a plethora of new possibilities, not only interesting from a fundamental physics point of view, but also for introducing the exotic functionalities of TMO’s into novel device concepts”, adds Dr. Pesquera
 

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).